Disease · EFO_1001352

Kartagener Syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Kartagener Syndrome. Diseases, record EFO_1001352. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001352

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Kartagener Syndrome; Open Targets
Open Targets ID: EFO_1001352; Open Targets
Other names: Kartagener's syndrome, PCD, primary ciliary dyskinesia; Open Targets
Disease Ontology: DOID:50144; Disease Ontology
MeSH: D007619; MeSH
NCI Thesaurus: C84797; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 3 of its 3 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IDREVLORIDE	CHEMBL5095031	Small molecule	Phase 2	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets
IVACAFTOR	CHEMBL2010601	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CFTR	Cystic fibrosis transmembrane conductance regulator	1	Cystic fibrosis transmembrane conductance regulator activator; Cystic fibrosis transmembrane conductance regulator positive modulator	Phase 2	https://conductscience.org/library/genes/1080	Drugs and targets
SCNN1A	Amiloride-sensitive sodium channel, ENaC	1	Amiloride-sensitive sodium channel, ENaC blocker	Phase 2	https://conductscience.org/library/genes/6337	Drugs and targets
SCNN1B	Amiloride-sensitive sodium channel, ENaC	1	Amiloride-sensitive sodium channel, ENaC blocker	Phase 2	https://conductscience.org/library/genes/6338	Drugs and targets
SCNN1G	Amiloride-sensitive sodium channel, ENaC	1	Amiloride-sensitive sodium channel, ENaC blocker	Phase 2	https://conductscience.org/library/genes/6340	Drugs and targets

Trials1

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by
NCT02871778	Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia	Phase 2	123	2021-12-16	Primary Ciliary Dyskinesia	IDREVLORIDE, IVACAFTOR, SODIUM CHLORIDE	Its record names the disease

Source ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
37660715	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001352

GET https://conductscience.org/api/diseases/v1/EFO_1001352/drugs

API reference For AI assistants